317 related articles for article (PubMed ID: 28422791)
1. Intrastructural help: improving the HIV-1 envelope antibody response induced by virus-like particle vaccines.
Temchura V; Überla K
Curr Opin HIV AIDS; 2017 May; 12(3):272-277. PubMed ID: 28422791
[TBL] [Abstract][Full Text] [Related]
2. Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines.
Elsayed H; Nabi G; McKinstry WJ; Khoo KK; Mak J; Salazar AM; Tenbusch M; Temchura V; Überla K
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743369
[TBL] [Abstract][Full Text] [Related]
3. Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells.
Storcksdieck genannt Bonsmann M; Niezold T; Temchura V; Pissani F; Ehrhardt K; Brown EP; Osei-Owusu NY; Hannaman D; Hengel H; Ackerman ME; Streeck H; Nabi G; Tenbusch M; Überla K
J Immunol; 2015 Nov; 195(10):4861-72. PubMed ID: 26466954
[TBL] [Abstract][Full Text] [Related]
4. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses.
Storcksdieck genannt Bonsmann M; Niezold T; Hannaman D; Überla K; Tenbusch M
Vaccine; 2016 Apr; 34(15):1744-51. PubMed ID: 26945099
[TBL] [Abstract][Full Text] [Related]
5. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
[TBL] [Abstract][Full Text] [Related]
6. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
[TBL] [Abstract][Full Text] [Related]
7. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
[TBL] [Abstract][Full Text] [Related]
8. Increased, Durable B-Cell and ADCC Responses Associated with T-Helper Cell Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.
Bogers WMJM; Barnett SW; Oostermeijer H; Nieuwenhuis IG; Beenhakker N; Mortier D; Mooij P; Koopman G; Remarque E; Martin G; Lai RP; Dey AK; Sun Y; Burke B; Ferrari G; Montefiori D; Martin L; Davis D; Srivastava I; Heeney JL
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701402
[TBL] [Abstract][Full Text] [Related]
9. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
[TBL] [Abstract][Full Text] [Related]
10. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
[TBL] [Abstract][Full Text] [Related]
11. Particle-based delivery of the HIV envelope protein.
Asbach B; Wagner R
Curr Opin HIV AIDS; 2017 May; 12(3):265-271. PubMed ID: 28422790
[TBL] [Abstract][Full Text] [Related]
12. GagPol-specific CD4⁺ T-cells increase the antibody response to Env by intrastructural help.
Nabi G; Genannt Bonsmann MS; Tenbusch M; Gardt O; Barouch DH; Temchura V; Uberla K
Retrovirology; 2013 Oct; 10():117. PubMed ID: 24156704
[TBL] [Abstract][Full Text] [Related]
13. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
[TBL] [Abstract][Full Text] [Related]
14. Effects of modification of the HIV-1 Env cytoplasmic tail on immunogenicity of VLP vaccines.
Vzorov AN; Wang L; Chen J; Wang BZ; Compans RW
Virology; 2016 Feb; 489():141-50. PubMed ID: 26761396
[TBL] [Abstract][Full Text] [Related]
15. Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.
Lewis GK; DeVico AL; Gallo RC
Proc Natl Acad Sci U S A; 2014 Nov; 111(44):15614-21. PubMed ID: 25349379
[TBL] [Abstract][Full Text] [Related]
16. Modulating the quantity of HIV Env-specific CD4 T cell help promotes rare B cell responses in germinal centers.
Lee JH; Hu JK; Georgeson E; Nakao C; Groschel B; Dileepan T; Jenkins MK; Seumois G; Vijayanand P; Schief WR; Crotty S
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33355623
[TBL] [Abstract][Full Text] [Related]
17. Germinal Center Lymphocyte Ratios and Successful HIV Vaccines.
Gonzalez-Figueroa P; Roco JA; Vinuesa CG
Trends Mol Med; 2017 Feb; 23(2):95-97. PubMed ID: 28089302
[TBL] [Abstract][Full Text] [Related]
18. Components of a HIV-1 vaccine mediate virus-like particle (VLP)-formation and display of envelope proteins exposing broadly neutralizing epitopes.
Rosengarten JF; Schatz S; Wolf T; Barbe S; Stitz J
Virology; 2022 Mar; 568():41-48. PubMed ID: 35101772
[TBL] [Abstract][Full Text] [Related]
19. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
Goepfert PA; Elizaga ML; Seaton K; Tomaras GD; Montefiori DC; Sato A; Hural J; DeRosa SC; Kalams SA; McElrath MJ; Keefer MC; Baden LR; Lama JR; Sanchez J; Mulligan MJ; Buchbinder SP; Hammer SM; Koblin BA; Pensiero M; Butler C; Moss B; Robinson HL; ;
J Infect Dis; 2014 Jul; 210(1):99-110. PubMed ID: 24403557
[TBL] [Abstract][Full Text] [Related]
20. IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine.
Sarkar S; Piepenbrink MS; Basu M; Thakar J; Keefer MC; Hessell AJ; Haigwood NL; Kobie JJ
Vaccine; 2019 Apr; 37(17):2322-2330. PubMed ID: 30926296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
